CDKN2A (p16) Promoter hypermethylation influences the outcome in young lung cancer patients

Diagnostic Molecular Pathology

Volumn 21, Issue 4, 2012, Pages 207-213

  Bradly, Dawn P ^a   Gattuso, Paolo ^a   Pool, Mark ^a   Basu, Sanjib ^a   Liptay, Michael ^a   Bonomi, Philip ^b   Buckingham, Lela ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

age; epigenetics; Lung cancer; methylation; p16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, P16; HUMANS; ILLINOIS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RADIOGRAPHY, THORACIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84870243374     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31825554b2     Document Type: Article

References (25)

1. Herman J, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349: 2042-2054. (Pubitemid 37448928)
2. de Jong W, Verpooten GF, Kramer H, et al. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer. Anticancer Res. 2009;29:363-369.
3. Buckingham L, Faber LP, Kim A, et al. and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II non small cell lung cancer patients. Int J Cancer. 2010;126:1630-1639.
4. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the deathassociated protein (DAP) kinase promoter and aggressiveness in stage I non-small cell lung cancer. J Natl Cancer Inst. 2000;92:1511-1516.
5. Burbee D, Forgacs E, Zochbauer-Miller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691-699. (Pubitemid 32492810)
6. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:2362-2368. (Pubitemid 34753611)
7. Brabender JUH, Metzger R, Schneider PM, et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003;9:223-227. (Pubitemid 36109737)
8. Kim D, Nelson HH, Wiencke JK, et al. p16 (INK4a) and histologyspecific methylationof CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001;61:3419-3424. (Pubitemid 32695035)
9. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 2004;91:771-774. (Pubitemid 39141639)
10. Brock M, Hooker CE, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118-1128. (Pubitemid 351398486)
11. Wang J, Lee JJ, Wang L, et al. Value of p16(INK4a) and RASSF1A promoter hypermethylation in prognosis of patients with respectable non-small cell lung cancer. Clin Cancer Res. 2004;10:6119-6125. (Pubitemid 39287517)
12. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12:7329-7338. (Pubitemid 46095405)
13. Russo A, Thiagalingam A, Pan H, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res. 2005;11:2466-2470. (Pubitemid 40569441)
14. Shell S, Park S-M, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci. 2007;104: 11400-11405. (Pubitemid 47175152)
15. Lu L, Katsaros D, Rigault IA, et al. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007; 67:10117-10122. (Pubitemid 350070782)
16. Guan H, Zhang P, Liu C, et al. Characterization and functional analysis of the human microRNA let-7a2 promoter in lung cancer A549 cell lines. Mol Biol Rep. 2011;38:5327-5334.
17. Buckingham L, Coon JS, Morrison LE, et al. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007;2:414-422. (Pubitemid 47181696)
18. Sobin L, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. Hoboken, New Jersey: John Wiley & Sons; 2002.
19. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
20. Gonzalo S. Epigenetic alterations in aging. J Appl Physiol. 2010;109:586-597.
21. Belshaw N, Pal N, Tapp HS, et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis. 2010;31:1158-1163.
22. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303:21-28.
23. Krishnamurthy J, Torrice C, RamseyMR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Investig. 2004;114:1299-1307. (Pubitemid 40385301)
24. Yap KLS, Munoz-Cabello AM, Raguz S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38:662-674.
25. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. 2011;71:5365-5369.